|
First
Enzyme Immunoassay for the Quantification of Plasma and Intracellular
Lopinavir in HIV Patients
The
protease
inhibitor lopinavir/LPV (Kaletra) is widely used in anti-human immunodeficiency virus (HIV) therapy.
Knowledge of the plasma and intracellular concentrations of the
drug would be useful for a better understanding of LPV action and
for therapeutic monitoring.
The
aim of this study was to develop a sensitive and specific immunoassay
for LPV in plasma and cells.
Anti-LPV
polyclonal antibodies were raised in rabbits using a synthetic LPV
derivative coupled to keyhole limpet hemocyanin (KLH) as immunogen.
The enzyme tracer was prepared by chemically coupling the LPV derivative
with acetylcholinesterase.
These
reagents were used to develop a competitive enzyme immunoassay (EIA)
performed in microtitration plates. The assay was performed on a
minimum of 50 mul of plasma or 2x10(6) cells. It showed good precision
and efficiency in as much as recovery from human plasma and cell
extracts spiked with LPV ranged between 87% and 104%, with coefficients
of variation of less than 10%.
The
limit of detection (LOD) was 100 pg/ml, i.e., a value at least 10
times lower than those currently achieved using previously described
techniques. Cross-validation with high-performance liquid chromatography
(HPLC) revealed a good correlation between methods (r(2)=0.96).
Intracellular
concentrations of LPV were measured in cultured human T lymphoblastoid
cells (CEM). A pharmacokinetic analysis of plasma and intracellular
LPV was performed on a healthy volunteer, and measurements were
done in patients infected with HIV.
The
results obtained indicated a high intracellular/extracellular concentration
ratio in cultured cells (19.3) but not in cells from HIV patients
(1.3).
In
contrast, in peripheral blood mononuclear cells (PBMC) the accumulation
of ritonavir (RTV) was six times higher than LPV.
The
authors conclude, “To date, this is the first reported immunoassay
for LPV, and this method is sensitive enough for monitoring plasma
and intracellular LPV levels in HIV-infected patients and for intracellular
studies.”
Laboratoire
de Chimie Bio-Organique UMR 6001, Faculte des Sciences, Universite
de Nice-Sophia Antipolis, Nice, France.
01/12/05
Reference
S
Azoulay and others. An enzyme immunoassay for the quantification
of plasma and intracellular lopinavir in HIV-infected patients.
Journal of Immunological Methods 295(1-2): 37-48. December
2004.
|